COVID-19 Pulmonary Pathology: The Experience of European Pulmonary Pathologists throughout the First Two Waves of the Pandemic.
CAPA
COVID-19
SARS-CoV-2
autopsy
lung pathology
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
01 01 2022
01 01 2022
Historique:
received:
22
11
2021
revised:
28
12
2021
accepted:
30
12
2021
entrez:
21
1
2022
pubmed:
22
1
2022
medline:
22
1
2022
Statut:
epublish
Résumé
Autoptic studies of patients who died from COVID-19 constitute an important step forward in improving our knowledge in the pathophysiology of SARS-CoV-2 infection. Systematic analyses of lung tissue, the organ primarily targeted by the disease, were mostly performed during the first wave of the pandemic. Analyses of pathological lesions at different times offer a good opportunity to better understand the disease and how its evolution has been influenced mostly by new SARS-CoV-2 variants or the different therapeutic approaches. In this short report we summarize responses collected from a questionnaire survey that investigated important pathological data during the first two pandemic waves (spring-summer 2020; autumn-winter 2020-2021). The survey was submitted to expert lung pathologists from nine European countries involved in autoptic procedures in both pandemic waves. The frequency of each lung lesion was quite heterogeneous among the participants. However, a higher frequency of pulmonary superinfections, both bacterial and especially fungal, was observed in the second wave compared to the first. Obtaining a deeper knowledge of the pathological lesions at the basis of this complex and severe disease, which change over time, is crucial for correct patient management and treatment. Autoptic examination is a useful tool to achieve this goal.
Identifiants
pubmed: 35054262
pii: diagnostics12010095
doi: 10.3390/diagnostics12010095
pmc: PMC8775196
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Netherlands Organisation for Health Research and Development
ID : 10430 01 201 0016
Références
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Lancet Infect Dis. 2021 Jun;21(6):e149-e162
pubmed: 33333012
J Infect. 2021 Jul;83(1):e32-e33
pubmed: 33932448
J Pathol. 2021 Jun;254(2):173-184
pubmed: 33626204
J Infect. 2021 Apr;82(4):84-123
pubmed: 33152376
Mycoses. 2021 Oct;64(10):1223-1229
pubmed: 34157166
Int J Mol Sci. 2021 Jan 19;22(2):
pubmed: 33478107
Transbound Emerg Dis. 2021 Mar;68(2):213-215
pubmed: 32892500
J Investig Allergol Clin Immunol. 2006;16(6):357-63
pubmed: 17153883
Cell Rep Med. 2021 Apr 20;2(4):100229
pubmed: 33748789
Mod Pathol. 2020 Nov;33(11):2156-2168
pubmed: 32879413
Lancet Respir Med. 2020 Dec;8(12):1201-1208
pubmed: 32861276